Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes


    loading  Checking for direct PDF access through Ovid

Abstract

HighlightsUnderstanding peptide degradation is useful to identify new drug targets.Rational drug design can be based on prior knowledge of an underlying mechanism.DPP-4 inhibitors were developed based on knowledge of incretin hormone biology.Clinical effects of DPP-4 inhibitors may involve additional physiological substrates.Dipeptidyl peptidase-4 (DPP-4) inhibitors are now a widely used, safe and efficacious class of antidiabetic drugs, which were developed prospectively using a rational drug design approach based on a thorough understanding of the endocrinology and degradation of glucagon-like peptide-1 (GLP-1). GLP-1 is an intestinal hormone with potent insulinotropic and glucagonostatic effects and can normalise blood glucose levels in patients with type 2 diabetes, but the native peptide is not therapeutically useful because of its inherent metabolic instability. Using the GLP-1/DPP-4 system and type 2 diabetes as an example, this review summarises how knowledge of a peptide's biological effects coupled with an understanding of the pathways involved in its metabolic clearance can be exploited in a rational, step-by-step manner to develop a therapeutic agent, which is effective and well tolerated, and any side effects are minor and largely predictable. Other peptides with metabolic effects which can also be degraded by DPP-4 will be reviewed, and their potential role as additional mediators of the effects of DPP-4 inhibitors will be assessed.

    loading  Loading Related Articles